StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Baird Maintains Bullish View on Gilead Sciences (GILD) Despite Top-Line Miss on U.S. Hep C Sales
April 29, 2016 7:30 AM
Baird analyst Brian Skorney reiterated an Outperform rating and $135 on Gilead Sciences (NASDAQ: GILD) despite a top-line miss driven ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS Change
Analyst EPS View
Next Articles
Gilead Sciences (GILD) PT Lowered to $118 at UBS
April 29, 2016 8:27 AM
Gilead Sciences (GILD) Receives Positive CHMP Opinion for Marketing Odefsey as HIV-1 Treatment
April 29, 2016 8:11 AM
Gilead Sciences (GILD) Needs M&A to Fill the Gap Following HCV Miss - BMO Capital
April 29, 2016 7:40 AM
Maxim Group Downgrades Gilead Sciences (GILD) to Hold
April 29, 2016 7:06 AM
Gilead Sciences (GILD) PT Trimmed to $123 at Leerink Partners
April 29, 2016 6:50 AM
Gilead Sciences (GILD) Misses Q1 EPS by 10c
April 28, 2016 4:05 PM
Gilead Sciences Announces First Quarter 2016 Financial Results
April 28, 2016 4:02 PM
